Assessment of columnar-lined esophagus in controls and patients with gastroesophageal reflux disease with and without proton-pump inhibitor therapy

European Surgery - Acta Chirurgica Austriaca

Volumn 44, Issue 5, 2012, Pages 304-313

  Mesteri, I ^a   Lenglinger, J ^a   Beller, L ^a   Fischer See, S ^a   Schoppmann, Sebastian F ^a   Wrba, F ^a,b   Riegler, F M ^a   Zacherl, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Institute for Clinical Pathology   (Austria)

Author keywords

Barrett's esophagus; Columnar lined esophagus; Dilated distal esophagus; Endoscopy; Gastroesophageal reflux disease; Histopathology; Squamooxyntic gap

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CARDIA; COLUMNAR EPITHELIUM; CONTROLLED STUDY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; SQUAMOUS EPITHELIUM; STOMACH GLAND; STOMACH MUCOSA;

EID: 84870470447     PISSN: 16828631     EISSN: 16824016     Source Type: Journal    
DOI: 10.1007/s10353-012-0159-7     Document Type: Article

References (54)

1. Becher A, Dent J. Systematic review: ageing and gastrooesophageal reflux disease symptoms, esophageal function and reflux oesophagitis. Aliment Pharmacol Ther. 2011;33(4):442-54.
2. Kamolz T, Velanovich V. The impact of disease and treatment on health-replated quality of life in patients suffering from GERD. In: Granderath FA, Kamolz T, Pointner R, editors. Gastroesophageal reflux disease, principles of disease, diagnosis and treatment. New York: Springer; 2006. 287-98.
3. Rieder F, Biancani P, Harnett K, et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol. 2010;298:G571-81.
4. Öberg S, Peters JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg. 1997;4(226):522-32. (Pubitemid 28049674)
5. Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care: the ProGERD study. Aliment Pharmacol Ther. 2012;35(1):154-64.
6. Chandrasoma PT, der R, Ma Y, Peters J, DeMeester T. Histologic classification of patients based on mapping biopsies of the gastroesophageal junction. Am J Surg Pathol. 2003;27(7):929-36. (Pubitemid 36758896)
7. Chandrasoma PT. Columnar lined esophagus: what it is and what it tells us. Eur Surg. 2006;38(3):197-209. (Pubitemid 44065126)
8. Chandrasoma P, Wijetunge S, Ma Y, DeMeester S, et al. The dilated distal esophagus: a new entity that is the pathologic basis of early gastroesophageal reflux disease. Am J Surg Pathol. 2011;35(12):1873-81.
9. Chandrasoma P, Wijetunge S, DeMeester SR, et al. The histologic squamo-oxyntic gap: an accurate and reproducible diagnostic marker of gastroesophageal reflux disease. Am J Surg Pathol. 2010;34(11):1574-81.
10. Odze RD. What the gastroenterologist needs to know about the histology of Barrett's esophagus. Curr Opin Gastroenterol. 2011;27(4):389-96.
11. Hvid-Jensen F, Pedersen L, Mohr Drewes A, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365:1375-83.
12. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2011. Epub ahead of print.
13. De Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett's oesophagus: Dutch nationwide cohort study. Gut. 2010;59(8):1030-6.
14. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2006;4:566-72. (Pubitemid 44308164)
15. Lenglinger J, Eisler M, Wrba F, et al. Update: histopathologybased definition of gastroesophageal reflux disease and Barrett's esophagus. Eur Surg. 2008;40(4):165-75.
16. Ringhofer C, Lenglinger J, Izay B, et al. Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr. 2008;120(11):350-9.
17. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344(8936):1533-6. (Pubitemid 24357710)
18. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanism, and endoscopic treatment of Barrett's esophagus. Gastroenterology. 2010;138(3):854-69.
19. Glickman JN, Spechler SJ, Souza RF, et al. Multilayered epithelium in mucosal biopsy specimens from the gastroesophageal junction region is a histologic marker of gastroesophageal reflux disease. Am J Surg Pathol. 2009;818-25.
20. Upton MP, Nishioka NS, Ransil BJ, et al. Multilayered epithelium may be found in patients with Barrett's esophagus epithelium and dysplasia or adenocarcinoma. Dig Dis Sci. 2006;51:1783-90.
21. Shi L, der R, Ma Y, et al. Gland ducts and multilayered epithelium in mucosal biopsies from gastroesophagealjunction region are useful in characterizing esophageal location. Dig Dis Esoph. 2005;18:87-92. (Pubitemid 40975419)
22. Riddell RH. The genesis of Barrett esophagus: has a histologic transition from gastroesophageal reflux disease-damaged epithelium to columnar metaplasia ever been seen in humans? Arch Pathol Lab Med. 2005;129(2):164-9. (Pubitemid 40204789)
23. Chandrasoma PT, der R, Dalton P, et al. Distribution and significance of epithelial types in columnar-lined esophagus. Am J Surg Pathol. 2001;25(9):1188-93. (Pubitemid 32777719)
24. Hamoui N, Lord RV, Hagen JA, et al. Response of the lower esophageal sphincter to gastric distention by carbonated beverages. J Gastrointest Surg. 2006;10:870-7. (Pubitemid 43850374)
25. Ayazi S, Tanhankar A, DeMeester SR, et al. The impact of gastric distension on the lower esophageal sphincter and its exposure to acid gastric juice. Ann Surg. 2010;252:57-62.
26. Glickman JN, Fox V, Antonioli DA, et al. Morphology of the cardia and significance of carditis in pediatric patients. Am J Surg Pathol. 2002;26(8):1032-9. (Pubitemid 34810564)
27. Sarbia M, Donner A, Gabbert HE. Histopathology of the gastroesophageal junction. A study on 36 operation specimens. Am J Surg Pathol. 2002;26(9):1207-12. (Pubitemid 34969190)
28. Chandrasoma P, Makarewicz K, Wickramasinghe K, et al. A proposal for a new validated histological definition of the gastroesophageal junction. Hum Pathol. 2006;37:40-7. (Pubitemid 41790501)
29. Chandrasoma PT, der R, Ma Y, et al. Histology of the gastroesophageal junction. An autopsy study. Am J Surg. 2000;24(3):402-9. (Pubitemid 30127476)
30. Theisen J, Stein HJ, Feith M, et al. Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia. Surg Endosc. 2006;20:235-8. (Pubitemid 43130254)
31. Chandrasoma P, Wickramasinghe K, Ma Y, et al. Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas. Am J Surg Pathol. 2007;31:569-75. (Pubitemid 46569041)
32. Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophagogastric junction. Scand J Surg. 2006;95(4):260-9.
33. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670-7. (Pubitemid 37500431)
34. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461-7. (Pubitemid 34827190)
35. Spechler SJ. Screening and surveillance for Barrett's esophagus: an unresolved dilemma. Nat Clin Pract Gastroenterol Hepatol. 2007;4(9):470-1. (Pubitemid 47371622)
36. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Eng J Med. 1999;340(11):825-31. (Pubitemid 29142625)
37. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinomas: a systematic review. Gastroenterology. 2002;122:26-33. (Pubitemid 34049191)
38. Bu X, Ma Y, der R, et al. Body mass index is associated with Barrett esophagus and cardiac mucosal metaplasia. Dig Dis Sci. 2006;51:1589-94. (Pubitemid 44379301)
39. Greer KB, Thompson CL, Brenner L, et al. Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut. 2011. Epub ahead of print.
40. Odze RD. Unraveling the mystery of the gastroesophageal junction: a pathologist's perspective. Am J Gastroenterol. 2005;100(8):1853-67. (Pubitemid 41648443)
41. Fleischer DE, Odze R, Overholt BF, et al. The case for endoscopic treatment of non-dysplastic and low grade dysplastic Barrett's esophagus. Dig Dis Sci. 2010;55:1918-31.
42. Sonnenberg A. Effects of environment and lifestyle on gastroesophageal reflux disease. Dig Dis. 2011;29(2):229-34.
43. Triadafilopoulos G. Proton pump inhibitor in Barrett's esophagus: pluripotent but controversial. Eur Surg. 2008;40(2):58-65. (Pubitemid 351685156)
44. Koch OO, Kaindlsdorfer A, Antoniou SA, et al. Laparoscopic Nissen versus Toupet fundoplication: objective and subjective results of a prospective randomized trail. Surg Endosc. Sep. 2011. Epub ahead of print.
45. Bonavina L, DeMeester T, Fockens P, et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure. Ann Surg. 2010;252(5):857-62.
46. Arora G, Basra S, Roorda AK, Triadafilopoulos G. Radiofrequency ablation for Barrett's esophagus. Eur Surg. 2009;41(1):19-25.
47. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus:5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42(10):781-9.
48. Hubbard N, Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus in patients with fundoplication. Surg Endosc. 2007;21:625-8. (Pubitemid 46439386)
49. dos Santos RS, Bizekis C, Ebright M, et al. Radiofrequency ablation fro Barrett's esophagus and low grade dysplasia in combination with antireflux procedure: a new paradigm. J Thorac Cardiovasc Surg. 2010;139(3):713-6.
50. O'Connell K, Velanovich V. Effects of Nissen fundplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus. Surg Endosc. 2011;25(3):830-4.
51. Goers TA, Leao P, Cassera MA, et al. Concomitant endoscopic radiofrequency ablation and laparoscopic reflux operative results in more effective and efficient treatment of Barrett's esophagus. J Am Coll Surg. 2011;213(4):486-92.
52. Sonnenberg A, Lash RH, Genta RG. A national study of Helicobacter pylori infection in gastric biopsy specimens. Gastroenterology. 2010;139:1894-901.
53. Wijetunge S, Ma Y, DeMeester S, et al. Association of adenocarcinomas of the distal esophagus, "gastroesophageal junction", and "gastric cardia" with gastric pathology. Am J Surg Pathol. 2010;34:1521-7.
54. Theodorou D, Ayazi S, DeMeester SR, et al. Intraluminal pH and goblet cell density in Barrett's esophagus. J Gastrointest Surg. 2011. Epub ahead of print.